Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 22;22(6):31.
doi: 10.1007/s11934-021-01050-0.

Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art

Michele Marchioni  1   2 , Juan Gomez Rivas  3 , Anamaria Autran  4 , Moises Socarras  5 , Simone Albisinni  6 , Matteo Ferro  7 , Luigi Schips  8 , Roberto Mario Scarpa  9 , Rocco Papalia  9 , Francesco Esperto  9
Affiliations
Review

Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art

Michele Marchioni et al. Curr Urol Rep. .

Abstract

Purpose of review: We aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification.

Recent findings: A wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients' risk stratification. Future prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.

Keywords: Biomarkers; Liquid biopsy; Renal cell carcinoma; miRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Marchioni M, Martel T, Bandini M, Pompe RS, Tian Z, Kapoor A, Cindolo L, Autorino R, Briganti A, Shariat SF, Schips L, Karakiewicz PI. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T(1-2) N(0) M(0) renal cell carcinoma. World J Urol. 2017;35:1899–1905. doi: 10.1007/s00345-017-2082-9. - DOI - PubMed
    1. Sohlberg EM, Metzner TJ, Leppert JT. The harms of overdiagnosis and overtreatment in patients with small renal masses: a mini-review. Eur Urol Focus [Internet]. 2019 [cited 2019 Apr 8]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2405456919300811 - PubMed
    1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–924. doi: 10.1016/j.eururo.2015.01.005. - DOI - PubMed
    1. Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A. Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis. Eur Urol Focus. 2019;5:857–866. doi: 10.1016/j.euf.2018.02.010. - DOI - PubMed

Substances